RxDoctor Payments Data

Michael Callaway, MD

Internal Medicine · Nashville, TNNPI 1588655153

Payments from drug & device makers

$280in general payments, 2019–2025

Across 16 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$84
  • Boehringer Ingelheim$49
  • AstraZeneca$36
  • GSK$24
  • Exact Sciences$20
  • Astellas Pharma US Inc$19
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC5$84
Boehringer Ingelheim3$49
AstraZeneca2$36
GSK1$24
Exact Sciences1$20
Astellas Pharma US Inc1$19
Novartis1$16
Novo Nordisk1$16
Alfasigma USA, Inc.1$16

How this compares

$280 in reported general payments places this provider in the 50th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$46,284
Medicare patients
108
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$71,390
OzempicSemaglutide30$30,977
JardianceEmpagliflozin19$20,768
MounjaroTirzepatide12$12,544
XareltoRivaroxaban12$7,749
Wixela InhubFluticasone Propion/Salmeterol13$3,539
Losartan Potassium147$2,380
Omeprazole117$2,282
Levothyroxine Sodium76$2,227
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$2,165
Gabapentin118$1,757
Metoprolol Succinate79$1,622
Atorvastatin Calcium123$1,271
SynthroidLevothyroxine Sodium15$1,206
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$30,97730 claims
Boehringer IngelheimJardiance$49$20,76819 claims
Lilly USA, LLCMounjaro$84$12,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →